Vidya Navaratnam1, Andrew W Fogarty2, Rachel Glendening2, Tricia McKeever2, Richard B Hubbard2. 1. Division of Epidemiology and Public Health, University of Nottingham, Nottingham, England; Nottingham Respiratory Research Unit, Nottingham City Hospital, Nottingham, England. Electronic address: vidya.navaratnam@nottingham.ac.uk. 2. Division of Epidemiology and Public Health, University of Nottingham, Nottingham, England.
Abstract
BACKGROUND: The lack of mandatory clinical registries for idiopathic pulmonary fibrosis (IPF) has meant a reliance on routine clinical data to provide trends in disease incidence. Death certificate and primary care data suggest that the incidence of IPF has increased in the United Kingdom at a rate of approximately 5% per year, but due to possible concerns about the diagnostic validity of these clinical datasets, it is helpful also to analyze data from secondary care. We used national secondary care data to determine trends in hospital admissions for IPF clinical syndrome (IPF-CS) in England between 1998 and 2010. METHODS: We obtained the annual number of hospital admissions for all National Health Service (NHS) hospital trusts in England for the International Classification of Diseases and Related Health Problems, 10th Revision codes J84.1 and J84.9 between 1998 and 2010. We calculated annual admission-rate ratios, adjusting for age and sex, using Poisson regression. We also investigated changes in age at admission and length of stay, and we estimated hospitalization costs. RESULTS: The number of hospital admissions from IPF-CS increased at an annual rate of approximately 5%, from 5,524 patients in 1998 to 9,525 patients in 2010, and was highest in men and the older population. Mean age at admission increased from 66 to 71 years, while length of stay decreased by 2.1 days during the same period. CONCLUSIONS: Hospital admissions for IPF-CS in England follow a similar trend to other data sources in the United Kingdom . This has resulted in escalating costs of inpatient care, which is a significant financial burden on health-care resources.
BACKGROUND: The lack of mandatory clinical registries for idiopathic pulmonary fibrosis (IPF) has meant a reliance on routine clinical data to provide trends in disease incidence. Death certificate and primary care data suggest that the incidence of IPF has increased in the United Kingdom at a rate of approximately 5% per year, but due to possible concerns about the diagnostic validity of these clinical datasets, it is helpful also to analyze data from secondary care. We used national secondary care data to determine trends in hospital admissions for IPF clinical syndrome (IPF-CS) in England between 1998 and 2010. METHODS: We obtained the annual number of hospital admissions for all National Health Service (NHS) hospital trusts in England for the International Classification of Diseases and Related Health Problems, 10th Revision codes J84.1 and J84.9 between 1998 and 2010. We calculated annual admission-rate ratios, adjusting for age and sex, using Poisson regression. We also investigated changes in age at admission and length of stay, and we estimated hospitalization costs. RESULTS: The number of hospital admissions from IPF-CS increased at an annual rate of approximately 5%, from 5,524 patients in 1998 to 9,525 patients in 2010, and was highest in men and the older population. Mean age at admission increased from 66 to 71 years, while length of stay decreased by 2.1 days during the same period. CONCLUSIONS: Hospital admissions for IPF-CS in England follow a similar trend to other data sources in the United Kingdom . This has resulted in escalating costs of inpatient care, which is a significant financial burden on health-care resources.
Authors: Simon L F Walsh; Toby M Maher; Martin Kolb; Venerino Poletti; Richard Nusser; Luca Richeldi; Carlo Vancheri; Margaret L Wilsher; Katerina M Antoniou; Jüergen Behr; Elisabeth Bendstrup; Kevin Brown; Lucio Calandriello; Tamera J Corte; Vincent Cottin; Bruno Crestani; Kevin Flaherty; Ian Glaspole; Jan Grutters; Yoshikazu Inoue; Maria Kokosi; Yasuhiro Kondoh; Vasileios Kouranos; Michael Kreuter; Kerri Johannson; Eoin Judge; Brett Ley; George Margaritopoulos; Fernando J Martinez; Maria Molina-Molina; António Morais; Hilario Nunes; Ganesh Raghu; Christopher J Ryerson; Moises Selman; Paolo Spagnolo; Hiroyuki Taniguchi; Sara Tomassetti; Dominique Valeyre; Marlies Wijsenbeek; Wim Wuyts; David Hansell; Athol Wells Journal: Eur Respir J Date: 2017-08-31 Impact factor: 16.671
Authors: Michael T Durheim; Harold R Collard; Rhonda S Roberts; Kevin K Brown; Kevin R Flaherty; Talmadge E King; Scott M Palmer; Ganesh Raghu; Laurie D Snyder; Kevin J Anstrom; Fernando J Martinez Journal: Lancet Respir Med Date: 2015-04-15 Impact factor: 30.700
Authors: Brett Ley; Jeffrey Swigris; Bann-Mo Day; John L Stauffer; Karina Raimundo; Willis Chou; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Mariola Kurowska-Stolarska; Manhl K Hasoo; David J Welsh; Lynn Stewart; Donna McIntyre; Brian E Morton; Steven Johnstone; Ashley M Miller; Darren L Asquith; Neal L Millar; Ann B Millar; Carol A Feghali-Bostwick; Nikhil Hirani; Peter J Crick; Yuqin Wang; William J Griffiths; Iain B McInnes; Charles McSharry Journal: J Allergy Clin Immunol Date: 2016-10-14 Impact factor: 10.793
Authors: Cathy Sampson; Ben Hope Gill; Nicholas Kim Harrison; Annmarie Nelson; Anthony Byrne Journal: BMC Pulm Med Date: 2015-12-04 Impact factor: 3.317
Authors: Eric S White; Zea Borok; Kevin K Brown; Oliver Eickelberg; Andreas Guenther; R Gisli Jenkins; Martin Kolb; Fernando J Martinez; Jesse Roman; Patricia Sime Journal: Am J Respir Crit Care Med Date: 2016-04-01 Impact factor: 21.405